Market Overview:
The global GALNT1 antibody market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for GALNT1 antibodies from bio-science companies, hospitals and clinics, universities and institutions, and others. Additionally, the increasing research on GALNT1 proteins is also contributing to the growth of this market. North America dominates the global GALNT1 antibody market followed by Europe and Asia Pacific.
Product Definition:
A GALNT1 antibody is a protein produced by the body's immune system in response to the presence of the GALNT1 antigen. The antibody binds to and neutralizes the antigen, preventing it from causing harm. The GALNT1 antibody is important for protecting against infection by pathogens that express the GALNT1 antigen.
pAbs:
pAbs, also known as protein-based assay is an immunological technique that uses antibodies to measure the binding of a particular protein in the cell. The most common pAbs used are those against glutamic acid (GALNT1), lysosome, and Tau proteins.
mAb:
mAb is short for monoclonal antibody. It is a protein made by B cells and it helps the immune system to identify and attack cancer cells, bacteria or viruses. The most common type of mAbs produced are antibodies against tumor antigens such as Epidermal Growth Factor Receptor (EGFR), HER2, insulin, and gastrin.
Application Insights:
BioScience companies were the largest revenue-generating segment in 2017. The application of galnt1 antibodies in the field of drug discovery and development is anticipated to witness a high growth rate during the forecast period. This can be attributed to increasing R&D costs coupled with an increase in focus on new drug development by major players such as Merck, Pfizer, and Amgen among others.
The University & institutions segment is expected to register a notable CAGR over the forecast period owing to rising number of research collaborations between universities and institutes along with private companies for developing novel therapeutics using galnt1 antibody probes for cancer diagnostics as well as treatment options.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology and pharmaceutical companies, coupled with high R&D investment by these firms, has fueled the regional growth. In addition, increasing government funding for cancer research is also expected to propel GALNT1 antibody sales over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in prevalence of cancer is further expected to boost demand for GALNT1 antibodies during the forecast period (2018-2030). For instance, according to NCBI data published on June 20th 2018; bladder cancer accounts for approximately 13% of all cancers diagnosed annually in China while it constitutes 14% of all cancers diagnosed annually globally (source: Trends Mol Med).
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the major growth drivers for the GALNT1 antibody market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing incidence rate of cancer is expected to drive demand for GALNT1 antibodies over the forecast period.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about early diagnosis and treatment options for various types of cancers. This has led to an increase in demand for diagnostic tests and therapies such as those that use GALNT1 antibodies.
- Technological advancements in antibody-based therapies: There have been significant advancements in technology used for developing antibody-based therapies over recent years. These technological advancements are expected to drive demand for GALNT1 antibodies over the forecast period as they offer better efficacy and safety profiles than traditional chemotherapy treatments options available currently..
Scope Of The Report
Report Attributes
Report Details
Report Title
GALNT1 Antibody Market Research Report
By Type
pAbs, mAb
By Application
BioScience Companies, Hospitals and Clinics, University and Institutions, Others
By Companies
Thermo Fisher Scientific, Biocompare, Abcam, RandD Systems, Novus Biologicals, Atlas Antibodies, Aviva Systems Biology, Biorbyt, 1DegreeBio, LifeSpan BioSciences, Inc, Thermo Fisher Scientific, CiteAb, Bioscience, Labochema, Sigmaaldrich
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global GALNT1 Antibody Market Report Segments:
The global GALNT1 Antibody market is segmented on the basis of:
Types
pAbs, mAb
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
BioScience Companies, Hospitals and Clinics, University and Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Thermo Fisher Scientific
- Biocompare
- Abcam
- RandD Systems
- Novus Biologicals
- Atlas Antibodies
- Aviva Systems Biology
- Biorbyt
- 1DegreeBio
- LifeSpan BioSciences, Inc
- Thermo Fisher Scientific
- CiteAb
- Bioscience
- Labochema
- Sigmaaldrich
Highlights of The GALNT1 Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- pAbs
- mAb
- By Application:
- BioScience Companies
- Hospitals and Clinics
- University and Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the GALNT1 Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The GALNT1 antibody is a protein that is specific to the galactose-alpha-1,3-galactosyltransferase 1 (GALT1) enzyme. This enzyme helps to transfer galactose from one molecule of glucose to another in the body. Galnt1 antibodies are used in research and diagnostics for diseases that involve abnormal galactose metabolism, such as lysosomal storage disorders and type I diabetes mellitus.
Some of the major players in the galnt1 antibody market are Thermo Fisher Scientific, Biocompare, Abcam, RandD Systems, Novus Biologicals, Atlas Antibodies, Aviva Systems Biology, Biorbyt, 1DegreeBio, LifeSpan BioSciences, Inc, Thermo Fisher Scientific, CiteAb, Bioscience, Labochema, Sigmaaldrich.
The galnt1 antibody market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 GALNT1 Antibody Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 GALNT1 Antibody Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 GALNT1 Antibody Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the GALNT1 Antibody Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global GALNT1 Antibody Market Size & Forecast, 2018-2028
4.5.1 GALNT1 Antibody Market Size and Y-o-Y Growth
4.5.2 GALNT1 Antibody Market Absolute $ Opportunity
Chapter 5 Global GALNT1 Antibody Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 GALNT1 Antibody Market Size Forecast by Type
5.2.1 pAbs
5.2.2 mAb
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global GALNT1 Antibody Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 GALNT1 Antibody Market Size Forecast by Applications
6.2.1 BioScience Companies
6.2.2 Hospitals and Clinics
6.2.3 University and Institutions
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global GALNT1 Antibody Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 GALNT1 Antibody Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America GALNT1 Antibody Analysis and Forecast
9.1 Introduction
9.2 North America GALNT1 Antibody Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America GALNT1 Antibody Market Size Forecast by Type
9.6.1 pAbs
9.6.2 mAb
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America GALNT1 Antibody Market Size Forecast by Applications
9.10.1 BioScience Companies
9.10.2 Hospitals and Clinics
9.10.3 University and Institutions
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe GALNT1 Antibody Analysis and Forecast
10.1 Introduction
10.2 Europe GALNT1 Antibody Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe GALNT1 Antibody Market Size Forecast by Type
10.6.1 pAbs
10.6.2 mAb
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe GALNT1 Antibody Market Size Forecast by Applications
10.10.1 BioScience Companies
10.10.2 Hospitals and Clinics
10.10.3 University and Institutions
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific GALNT1 Antibody Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific GALNT1 Antibody Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific GALNT1 Antibody Market Size Forecast by Type
11.6.1 pAbs
11.6.2 mAb
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific GALNT1 Antibody Market Size Forecast by Applications
11.10.1 BioScience Companies
11.10.2 Hospitals and Clinics
11.10.3 University and Institutions
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America GALNT1 Antibody Analysis and Forecast
12.1 Introduction
12.2 Latin America GALNT1 Antibody Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America GALNT1 Antibody Market Size Forecast by Type
12.6.1 pAbs
12.6.2 mAb
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America GALNT1 Antibody Market Size Forecast by Applications
12.10.1 BioScience Companies
12.10.2 Hospitals and Clinics
12.10.3 University and Institutions
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) GALNT1 Antibody Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) GALNT1 Antibody Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) GALNT1 Antibody Market Size Forecast by Type
13.6.1 pAbs
13.6.2 mAb
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) GALNT1 Antibody Market Size Forecast by Applications
13.10.1 BioScience Companies
13.10.2 Hospitals and Clinics
13.10.3 University and Institutions
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 GALNT1 Antibody Market: Competitive Dashboard
14.2 Global GALNT1 Antibody Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Thermo Fisher Scientific
14.3.2 Biocompare
14.3.3 Abcam
14.3.4 RandD Systems
14.3.5 Novus Biologicals
14.3.6 Atlas Antibodies
14.3.7 Aviva Systems Biology
14.3.8 Biorbyt
14.3.9 1DegreeBio
14.3.10 LifeSpan BioSciences, Inc
14.3.11 Thermo Fisher Scientific
14.3.12 CiteAb
14.3.13 Bioscience
14.3.14 Labochema
14.3.15 Sigmaaldrich
